FDA 21 CFR Part 11 Questions and Answers (36 FAQs)

FDA 21 CFR Part 11 is a U.S. Food and Drug Administration (FDA) regulation that sets the requirements for the use of electronic records and electronic signatures. FDA 21 CFR Part 11 ensures that electronic records and signatures are trustworthy, reliable, and secure, and can be considered equivalent to paper records and handwritten signatures. The regulation applies to FDA-regulated life science companies, including pharmaceuticals, biotechnology, and medical devices, that rely on computerized systems to manage records required by FDA regulations.

This article contains 36 frequently asked questions (FAQs) and answers about FDA 21 CFR Part 11. The FAQs provide clear and concise guidance for professionals navigating FDA 21 CFR Part 11 compliance, explaining the regulation’s scope and key requirements. The FAQs cover electronic records, electronic signatures, audit trails, validation, and practical steps for implementing compliant systems.

What Is FDA 21 CFR Part 11?

FDA 21 CFR Part 11 is a regulation issued by the US FDA governing the use of electronic records and signatures. FDA 21 CFR Part 11 outlines requirements under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures.

When Did the 21 CFR Part 11 Regulations Go Into Effect?

The 21 CFR Part 11 regulation came into effect on August 20, 1997, following its publication by the US FDA on March 20, 1997. The regulation remains in effect today, with the most recent update issued on March 2, 2023.

What Is the History of 21 CFR Part 11?

The history of 21 CFR Part 11 began with its publication by the US FDA on March 20, 1997, and its effective date of August 20, 1997. 21 CFR Part 11 was established to ensure electronic records and electronic signatures used in FDA-regulated industries could be considered equivalent to paper records and handwritten signatures.

21 CFR Part 11 introduced requirements for system validation, audit trails, secure user authentication, and electronic signature controls. Challenges within the industry related to interpretation and implementation led the FDA to issue guidance in September 2003, clarifying that enforcement would focus on records required by FDA predicate rules and would follow a risk-based approach. Since then, 21 CFR Part 11 has remained a core regulation governing electronic record-keeping and compliance in pharmaceuticals, biotechnology, and medical devices.

What Is the Purpose of the FDA 21 CFR Part 11?

The main purpose of FDA 21 CFR Part 11 is to ensure that electronic records and electronic signatures used in FDA-regulated industries are trustworthy, reliable, and equivalent to paper records and handwritten signatures.

FDA 21 CFR Part 11 sets criteria for system validation, secure access, audit trails, and electronic signature controls. These requirements ensure that digital records remain accurate, protected from tampering and unauthorized changes, and fully traceable throughout their lifecycle.

What Are the Benefits of Complying With 21 CFR Part 11?

The benefits of complying with 21 CFR Part 11 are listed below.

• Improved Data Integrity: 21 CFR Part 11 ensures electronic records are accurate, complete, and consistent, and reinforces compliance through validation and audit trail requirements.
• Enhanced Regulatory Compliance: Meeting 21 CFR Part 11 demonstrates an organization’s commitment to FDA regulations, data integrity, security, and reliability.
• More Efficient Operational Processes: 21 CFR Part 11reduces reliance on manual paperwork and accelerates digital transformation by enabling automated electronic signatures, paperless documentation, and faster approvals.
• Streamlined Collaboration: FDA 21 CFR Part 11 provides secure electronic systems that support multi-site data sharing, real-time decision-making, and faster cross-departmental collaboration and approvals.
• Improved Auditability: FDA 21 CFR Part 11 simplifies internal reviews and external FDA audits by requiring validated audit trails, time-stamped records, and linked electronic signatures.
• Increased Security: Compliance with mandatory security controls, such as user authentication protocols, role-based access management, and data encryption requirements outlined in 21 CFR Part 11, safeguards sensitive information and records.
• Simplified Recordkeeping: FDA 21 CFR Part 11 benefits organizations by replacing physical archives with electronic recordkeeping, lowering administrative burden, improving organization, and ensuring inspection-ready storage of records.

Who Does 21 CFR Part 11 Apply To?

21 CFR Part 11 applies to all companies regulated by the US FDA that use electronic records and electronic signatures in place of paper records and handwritten signatures. This includes organizations in pharmaceutical, biotechnology, medical device, and other life science sectors, involved in developing, manufacturing, testing, or distributing FDA-regulated products.

For example, in the pharmaceutical industry, 21 CFR Part 11 governs the use of electronic systems for Good Manufacturing Practice (GMP) activities, including batch records, standard operating procedures (SOPs), deviations and nonconformances, and other quality documentation.

In medical devices, 21 CFR Part 11 applies to Quality System Regulation (21 CFR Part 820) records, including design controls, corrective action, and preventive actions (CAPAs), complaints, audits, and any other documentation requiring secure electronic records and signatures.

When Does 21 CFR Part 11 Apply?

21 CFR Part 11 applies whenever electronic records and electronic signatures are used and managed for activities subject to FDA regulations. It applies to a range of FDA-regulated activities within the pharmaceutical, biotechnology, medical device, and related industries, including different stages of product development, such as research and development, manufacturing, and distribution.

Would you like to assess whether you need to comply with the regulation? You can use the 21 CFR Part 11 applicability assessment to determine if your system for managing electronic records and signatures needs to comply with the 21 CFR Part 11 requirements.

What Is a 21 CFR Part 11 Applicability Assessment?

A 21 CFR Part 11 applicability assessment is the process of determining whether electronic records and electronic signatures used in a system fall under the scope of FDA 21 CFR Part 11. The 21 CFR Part 11 applicability assessment identifies records required by FDA predicate rules, evaluates system features, and defines necessary controls such as system validation, audit trails, and security measures to ensure compliance.

What Are the Predicate Rules Under 21 CFR Part 11?

Predicate rules under 21 CFR Part 11 are FDA regulations and statutory requirements, as outlined in the Federal Food, Drug, and Cosmetic Act (FD&C Act), the Public Health Service Act (PHS Act), and related FDA regulations, that define which records must be created and maintained. Examples of predicate rules include Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Laboratory Practice (GLP).

21 CFR Part 11 does not replace these predicate rules requirements; instead, it specifies how electronic records and electronic signatures required by predicate rules must be managed. This includes controls for electronic records, electronic signatures, and computer systems. Companies using electronic systems under predicate rules such as 21 CFR Parts 210, 211, and 820 must also comply with 21 CFR Part 11 requirements.

What Does 21 CFR Part 11 Compliance Mean?

21 CFR Part 11 compliance refers to adhering to the requirements outlined in 21 CFR Part 11. 21 CFR Part 11 compliance ensures a company’s electronic records and electronic signatures meet FDA requirements for trustworthiness, reliability, and equivalence to paper records and handwritten signatures. Compliance requires validated systems, secure access controls, audit trails, and safeguards that ensure data integrity, accountability, and regulatory acceptance.

How Can You Ensure FDA 21 CFR Part 11 Compliance?

To ensure FDA 21 CFR Part 11 compliance, key steps are recommended below.

1. Validate Systems: Implement a documented validation lifecycle. System validation includes documented protocols confirming system accuracy, reliability, and performance under expected conditions. Proper validation also involves change control, periodic reviews, and traceable user acceptance testing aligned with GxP requirements.
2. Implement Role-Based Access Controls: Enforce strong authentication protocols such as unique user credentials, password expiration policies, and optional multi-factor authentication. Access control should reflect job responsibilities to prevent unauthorized actions and ensure accountability.
3. Maintain Time-Stamped Audit Trails: Uphold secure, computer-generated audit trails that capture all data creation, modifications, and deletions. These audit logs should include metadata such as time, date, user ID, and reason for change, supporting traceability and data integrity throughout system usage.
4. Assign Unique User IDs: Each system user should have a distinct login credential to enforce accountability and prevent shared access. Unique identifiers help ensure digital signature compliance and support effective tracking within audit logs and system usage reports.
5. Apply Verified Electronic Signatures: Electronic signatures must be uniquely linked to verified user identities. These digital approvals must meet the criteria for authenticity, non-repudiation, and equivalency to handwritten signatures under the electronic records and signatures rule.
6. Document System Procedures: SOPs must govern all aspects of system use, from data entry to inspection readiness. Include SOP version control, signature application protocols, and documented workflows for handling electronic records in a compliant manner.
7. Conduct Ongoing Training: Organizations must conduct regular training and maintain up-to-date training records. Training should cover regulatory expectations, changes in system functionality, and evolving best practices in Part 11 audit readiness and QMS integration.
8. Ensure Secure Record Retention and Availability: Implement controls to protect records from unauthorized access, alteration, or deletion, including encryption, backup, and disaster recovery procedures. Electronic records must be maintained, retrievable, and inspection-ready in accordance with predicate rules.
9. Perform Periodic System Reviews: Conduct documented periodic reviews to confirm the system remains validated, secure, and fit for intended use, including review of access rights, audit trails, configurations, SOPs, incidents, and regulatory changes impacting 21 CFR Part 11 compliance.
10. Conduct Internal Audits for Part 11 Compliance: Perform documented internal audits to verify ongoing compliance with FDA 21 CFR Part 11, including validation status, access controls, audit trails, electronic signatures, SOP adherence, and record retention, with findings tracked to CAPA and management review.

What Should a 21 CFR Part 11 Compliant System Be Able to Do?

A 21 CFR Part 11 compliant system should be able to demonstrate the capabilities below.

• Manage Electronic Records: A compliant system to 21 CFR Part 11 must be capable of creating, modifying, versioning, and retrieving electronic records while maintaining accuracy, completeness, and security throughout the record lifecycle. A compliant system must also support controlled record versioning and metadata capture for every record update.
• Generate Secure Audit Trails: The system must provide immutable, computer-generated, and time-stamped audit trails that log all changes to records. Each entry should capture who performed the action, what was changed, when it occurred, and why, to support real-time traceability and audit integrity.
• Control Access with Role-Based Authentication: Role-based access control (RBAC) must be enforced to ensure only authorized users can access specific functions or data. The system should support unique user IDs, user access provision and deactivation, role-specific access permissions, and secure authentication credentials.
• Apply Verified Electronic Signatures: Electronic signatures must be uniquely linked to the respective user ID, and include signature time-stamping and manifestation (display of name, date, and reason). Verified electronic signatures ensure compliance with signature authenticity and non-repudiation requirements.
• Protect Data Integrity: The system must safeguard electronic records from tampering, unauthorized access, or untracked changes. A compliant system involves a secure system architecture and controls that ensure authenticity, legibility, and retrievability across the full data lifecycle.
• Ensure Inspection and FDA Readiness: A Part 11 compliant system should maintain all validated records in a format readily accessible for FDA audits and regulatory inspections. Documented SOPs, automated logs, and training records should be audit-ready at all times.

What Are the Five Most Common 21 CFR Part 11 Noncompliance Issues?

The five most common 21 CFR Part 11 noncompliances, based on the FDA inspection data from 2016 to 2020, are described below.

1. Audit Trails: Many systems lack secure, computer-generated, time-stamped audit trails that capture who performed an action, what was changed, and when it occurred. Missing metadata, weak or non-synchronized timestamps, and non-permanent audit logs undermine compliance and data integrity.
2. Records Retention Period: Noncompliance often arises when electronic records are not stored for the required retention period or when long-term archival and retrieval protocols are inadequate.
3. System Access Controls: Weak access controls, such as poor password policies, lack of role-based permissions, or failure to assign unique user IDs, lead to unauthorized access and compromised electronic records and signatures.
4. System Validation: Systems are often implemented without adequate validation, including a lack of documented functionality testing, incomplete user requirement specifications (URS), or inadequate change control records.
5. System Documentation Control and Signature Record Linking: Compliance failures occur when procedures and policies for electronic systems are outdated or incomplete. Additional issues include improper linkage of electronic signatures to their corresponding records.

What Are the Three Primary Areas of 21 CFR Part 11?

The three primary areas of 21 CFR Part 11 are listed below.

• Subpart A General Provisions: Subpart A defines 21 CFR Part 11’s scope and applicability and provides key definitions for terms used throughout the regulation.
• Subpart B Electronic Records: Subpart B specifies requirements for creating, modifying, and maintaining electronic records. Subpart B includes controls and procedures for ensuring data integrity and security, implementing audit trails, and limiting system access.
• Subpart C Electronic Signatures: Subpart C outlines the requirements for proper use and controls of electronic signatures, including controls for identification codes and passwords.

What Are 21 CFR Part 11 Requirements?

The brief 21 CFR Part 11 requirements overview is listed below.

• 21 CFR 11.1 Scope of Regulation (Subpart A): 21 CFR 11.1 establishes the applicability of 21 CFR Part 11 to electronic records and signatures used in FDA-regulated activities, including life sciences industries.
• 21 CFR 11.2 Implementation (Subpart A): 21 CFR 11.2addresses how electronic records and electronic signatures are considered equivalent to paper records and handwritten signatures under FDA rules.
• 21 CFR 11.3 Definitions (Subpart A): 21 CFR 11.3 provides key regulatory definitions such as “closed system”, “open system”, “electronic record”, and “digital signature”, which influence compliance scope and implementation.
• 21 CFR 11.10 Controls for Closed Systems (Subpart B): 21 CFR 11.10 requires controls such as secure system access, audit trails, operational checks, and system validation to ensure data integrity in environments where system access is controlled by individuals responsible for the records.
• 21 CFR 11.30 Controls for Open Systems (Subpart B): 21 CFR 11.30mandates additional security measures, such as encryption and digital signature standards, for systems where access is not controlled by individuals responsible for the records.
• 21 CFR 11.50 Signature Manifestations (Subpart B): 21 CFR 11.50specifies that signed electronic records must include the printed name, date/time of signature, and the reason for signing (e.g., approval, review, etc.).
• 21 CFR 11.70 Signature/Record Linking (Subpart B): 21 CFR 11.70 requires that electronic signatures (and handwritten signatures executed to electronic records) be permanently and securely linked to their associated records, ensuring they cannot be excised, copied, or falsified.
• 21 CFR 11.100 General Requirements for Electronic Signatures (Subpart C): 21 CFR 11.100requires that each electronic signature be unique, with verification of user identity before assignment, and that users certify that their signatures are the legally binding equivalent of handwritten signatures.
• 21 CFR 11.200 Electronic Signature Components and Controls (Subpart C): 21 CFR 11.200details specific controls for electronic signatures, including the use of two distinct identification components, such as a unique user ID and a password, to ensure authenticity and prevent forgery.
• 21 CFR 11.300 Controls for Identification Codes and Passwords (Subpart C): 21 CFR 11.300requires procedures for managing system access credentials, including periodic checks, password expiration, limits on reuse, and safeguards such as deactivation or lockout after repeated failed login attempts.

What Are 21 CFR Part 11 Requirements for Electronic Records?

An electronic record under 21 CFR Part 11 means any combination of text, graphics, data, audio, pictorial, or other information representation in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer system.

All 21 CFR Part 11 requirements for electronic records are detailed in Subpart B and are discussed below.

• 21 CFR 11.10 Controls for Closed Systems: A closed system for electronic records must implement system validation, authorized access controls, and secure audit trails, ensuring the protection and ready retrieval of accurate and complete records throughout the required retention period. Other requirements include operational and authority checks, trained personnel, and controlled system documentation.
• 21 CFR 11.30 Controls for Open Systems: Open systems must implement the controls identified in 11.10 as appropriate, plus additional measures such as document encryption and digital signature standards to ensure the authenticity, integrity, and confidentiality of electronic records during transmission and access.
• 21 CFR 11.50 Signature Manifestations: All electronic signatures must clearly display the signer’s full name, date/time of signing, and purpose of the signature (e.g., approval, review). This requirement ensures the identification and transparency of the signer’s role for audit and legal validation purposes.
• 21 CFR 11.70 Signature and Record Linking: Electronic signatures must be permanently linked to the corresponding electronic records using a tamper-evident record design. The system must prevent these signatures from being removed, falsified, or misapplied, preserving data authenticity and ensuring traceability.

What Is the Difference Between Open and Closed Systems in 21 CFR Part 11?

The main difference between open and closed systems under FDA 21 CFR Part 11 lies in access control. A closed system is managed by those responsible for the electronic records, with compliance ensured through validation, secure user IDs and passwords, audit trails, and electronic signatures.

In contrast, an open system is not directly controlled by those responsible for the records. In addition to the controls required for closed systems, open systems must implement extra safeguards such as encryption and digital signatures to maintain the authenticity, integrity, and confidentiality of electronic records.

What Does Accurate Record Generation Mean Under 21 CFR Part 11?

Accurate record generation means creating and storing electronic records in a way that ensures accuracy, reliability, and data integrity, as required by 21 CFR 11.10(b). The records must faithfully represent the original captured information without intentional or unintentional alterations or discrepancies, ensuring that accurate and complete copies can be retrieved in a format suitable for inspection, review, and copying by the FDA.

What Does Limited System Access Mean in the Context of 21 CFR Part 11?

Limited system access under 21 CFR Part 11 means restricting the use of electronic recordkeeping systems to authorized individuals only. Access is controlled through unique user IDs, secure passwords, role-based permissions, and identity verification to prevent unauthorized entry, data changes, or record manipulation, ensuring compliance with 21 CFR 11.10(d).

Enforcement of limited access involves applying measures such as role-based access control, multifactor authentication, and transaction safeguards that prevent unauthorized use of codes or passwords. These controls ensure that only personnel with defined responsibilities can create, modify, or access electronic records, protecting data integrity and regulatory compliance.

How Can You Enforce Limited Access for Users Under 21 CFR Part 11?

To enforce limited access for users under 21 CFR Part 11, several approaches are given below.

• Unique Identification Codes and Passwords: Each user must be assigned a distinct ID and password combination to establish accountability. Supporting measures include password expiration policies, complexity rules, and account lockout after repeated failed login attempts.
• Role-Based Access Control (RBAC): System access should be restricted according to user roles and responsibilities. RBAC prevents unauthorized actions and ensures personnel can only perform tasks aligned with their function. Proper user access provisioning and revocation processes are essential.
• Multifactor Authorization: Strengthen authentication with two-factor or biometric verification to reduce risks of credential theft. Multifactor controls add a critical layer of identity assurance beyond passwords.
• Transaction Safeguards: Implement technical measures to prevent the misuse of identification codes and passwords, such as session timeouts, automatic logouts, and device-based restrictions that block repeated unauthorized attempts.
• User Identity Verification: Before issuing credentials, organizations must verify the identity of each user and maintain records of this verification. Ongoing reviews and deactivation of inactive accounts ensure compliance with 21 CFR 11.300 controls for identification codes and passwords.

What Is Computer System Validation Under 21 CFR Part 11?

Computer system validation (CSV) under 21 CFR Part 11 is the documented process of ensuring that a computerized system consistently meets its intended use, functions as designed, and complies with FDA regulations. While CSV principles derive from broader FDA guidance and GxP requirements, 21 CFR Part 11 specifically requires validation to ensure the accuracy, reliability, and consistent intended performance and the ability to discern invalid or altered records, as stated in 21 CFR 11.10(a).

Computer system validation is required when implementing new systems or making significant modifications to existing systems. It applies to computerized systems that create, modify, maintain, or transmit electronic records or electronic signatures subject to FDA oversight, making it a cornerstone of regulatory compliance under 21 CFR Part 11.

What Is a 21 CFR Part 11 Validation Protocol?

A 21 CFR Part 11 validation protocol is a documented plan that defines how a computerized system will be tested and verified to demonstrate compliance with 21 CFR Part 11 requirements. The validation protocol specifies validation strategy, objectives, scope, responsibilities, requirements traceability, and detailed test procedures such as Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). Other elements in the validation protocol include predefined acceptance criteria and documentation to prove the system is accurate, reliable, and fit for use.

What Approach Is Recommended for Validating Electronic Systems?

The recommended approach for validating electronic systems is a risk-based approach, as outlined in industry guidance such as the International Society for Pharmaceutical Engineering (ISPE) GAMP5.

The recommended approach for validating electronic systems aligned with GAMP5 guidelines includes the following.

• Validation Planning: Establish a Validation Master Plan (VMP) that defines the validation strategy, objectives, scope, responsibilities, acceptance criteria, and documentation requirements. This validation plan should align with GxP and Part 11 compliance requirements and integrate with the organization’s quality management system (QMS).
• Risk Management: Perform a formal risk assessment to identify, evaluate, and mitigate risks to product quality, patient safety, and data integrity. Testing efforts should be prioritized based on risk impact, ensuring high-risk functions and critical GxP processes undergo the most rigorous evaluation.
• Specifications Development: Document User Requirements Specifications (URS) and Functional Requirements Specifications (FRS) that define what the system must do and how it will perform. These specifications form the foundation for qualification testing.
• Installation Qualification (IQ): Verify and document that the system is installed according to vendor specifications and operates within the intended technical environment. IQ protocols typically check hardware configurations, software installation, system architecture, and network connectivity.
• Operational Qualification (OQ): Execute OQ test protocols to confirm that all functions, features, workflows, and Part 11 controls operate as intended under controlled, expected conditions. Test evidence should be mapped back to the functional requirements specification (FRS).
• Performance Qualification (PQ): Demonstrate through PQ testing that the system performs reliably, accurately, and consistently in the actual production environment using real-world scenarios and representative data. Results should be linked back to the user requirements specification (URS).
• Traceability: Maintain a requirements traceability matrix (RTM) linking URS, FRS, test protocols, and results. Traceability ensures every regulatory and business requirement is tested and validated with documented evidence.
• Validation Reporting: Summarize testing activities, results, and any deviations in a final validation report. Confirm the system is in a validated state, supported by documented evidence, and issue formal approval signatures confirming validation completion. Reports should also define change control procedures and plans for periodic review to maintain the validated state over time.

What Are the Audit Trail Requirements Under 21 CFR Part 11?

An audit trail under 21 CFR Part 11 is a secure, computer-generated, time-stamped record that documents all user actions and system activities related to the creation, modification, or deletion of electronic records. Audit trail provides a reliable mechanism to track and verify the integrity and authenticity of records throughout their lifecycle.

The 21 CFR Part 11 audit trail requirements are listed below.

• Ensure Audit Trail Security: According to 21 CFR 11.10(d) and 11.10(e), audit trails must be secure and protected from unauthorized access. Audit trail security is maintained through robust access controls, authentication mechanisms, and role-based permissions, ensuring they remain immutable and tamper-evident throughout the record lifecycle.
• Implement Computer-Generated Audit Trails: Audit trails must be automatically generated by the system, not manually created, to prevent errors and manipulation as outlined in 21 CFR 11.10(e). Every entry should include chronological logging of events with metadata.
• Automate Time-Stamping: As per section 21 CFR 11.10(e), audit trail entries must include accurate, system-generated time stamps that record the date and time of each action that creates, modifies, or deletes electronic records. Time stamps should be synchronized to a reliable time source. Use of coordinated universal time (UTC) or a system-standardized time zone is recommended.
• Verify User Identity: Audit trails must independently capture the identity of the user performing each action. Authority checks under 21 CFR 11.10(g) ensure only authorized personnel can access or modify records.
• Track Performed Actions: Every action that creates, modifies, or deletes electronic records must be logged. Audit trails should document what action was performed and which record was affected.
• Preserve Previously Recorded Information: Record changes should not obscure previously recorded information as outlined in 21 CFR 11.10(e). When electronic records are modified, both original and new values must be captured and remain accessible.
• Retain Audit Trail Documentation: As stated in 21 CFR 11.10(e), audit trails must be retained for as long as the associated record is required. Audit trail retention also involves policies, secure storage, backups, and disaster recovery procedures.
• Ensure Audit Trail Availability for FDA Inspection: Audit trails must be readily available for regulatory review and copying during FDA inspections according to 21 CFR 11.10(e). Systems should allow for easy retrieval of audit data and enable export in formats suitable for regulatory inspection.

What Are Operational System Checks According to 21 CFR Part 11?

Operational system checks according to 21 CFR Part 11 are automated controls within electronic systems that enforce the correct sequencing of steps and events, as required by 21 CFR 11.10(f). These operational checks ensure operations are performed in the intended order and prevent users from skipping critical steps or performing actions out of sequence. Operational system checks are implemented, where appropriate, based on the criticality of process sequencing to product quality, data integrity, or compliance.

What Are Device Checks According to 21 CFR Part 11?

Device checks according to 21 CFR Part 11 are system controls used to verify the validity and reliability of data input sources or operational instructions in electronic systems, as required by 21 CFR 11.10(h). These device checks confirm that devices, such as terminals, workstations, or instruments, attempting to input data or issue commands to the system are authorized and legitimate. This ensures that entered data or operational instructions are accurate and suitable for intended operations. Implementation is risk-based, where unauthorized device access could compromise data integrity or system security.

What Are the Training Record Requirements Under 21 CFR Part 11?

Under 21 CFR Part 11.10(i), organizations must determine and document that all persons who develop, maintain, or use electronic record and electronic signature systems have the appropriate education, training, and experience to perform their assigned tasks.

To support training record compliance with 21 CFR Part 11.10(i), organizations should ensure that the records and requirements listed below are available.

• Qualified System Users: Personnel are trained on system use, Part 11 responsibilities, and electronic signature practices before being granted access.
• Role-Appropriate Training: Training content aligns with user roles, e.g., end users, administrators, and validators.
• Documented Training Evidence: Training completion and competency are documented and retained as electronic records subject to Part 11 controls.
• Electronic Record Controls for Training Records: Training records meet applicable Part 11 requirements, including validation (11.10(a)), secure access (11.10(d)), audit trails (11.10(e)), accurate copies (11.10(b)), and reliable retrieval (11.10(c)).
• Electronic Signatures for Training Acknowledgment: E-signatures comply with 11.50 and are permanently linked to records (11.70), where used.
• Ongoing Competency and Refresher Training: Training remains current through periodic review, retraining after system changes, and effectiveness assessment.

What Is a Policy of Responsibility Under 21 CFR Part 11 for Using Electronic Signatures?

A policy of responsibility or accountability for using electronic signatures under 21 CFR Part 11 is a written document that defines rules and guidelines for applying electronic signatures within a company, as required by 21 CFR 11.10(j). This policy of responsibility states that electronic signatures are the legally binding equivalent of handwritten signatures and ensures individuals are accountable for actions performed under their electronic signatures, in order to deter falsification of records and signatures.

This policy of responsibility is often formalized as an Electronic Signature Agreement (ESA), signed by all users, acknowledging that their electronic signature carries the same legal weight and accountability as a handwritten signature. It also provides documented assurance that users accept full responsibility for their actions executed under those signatures.

What Are the Electronic Signature Requirements Under 21 CFR Part 11?

An electronic signature under 21 CFR Part 11 is a computer data compilation of any symbol or series of symbols executed, adopted, or authorized by an individual to be the legally binding equivalent of the individual’s handwritten signature.

The electronic requirements under 21 CFR Part 11 are itemized below.

• Uniqueness and Identity Verification: According to §11.100(a–b), each electronic signature must be unique to one individual, not reused or reassigned, and issued only after the organization verifies the person’s identity.
• Legally Binding: In §11.100(c), companies must certify to the FDA that electronic signatures in their system are intended to be legally binding equivalents of handwritten signatures.
• Signature Components: Non-biometric electronic signatures must use at least two distinct identification components (such as an identification code and password) as outlined in §11.200(a). §11.200(b) specifies that biometric signatures must be designed so that only the genuine owner can use them.
• Auditability and Accountability: As per §11.200(a)(2–3), requires that electronic signatures be used only by their genuine owners and that attempted misuse would require the collaboration of two or more individuals. These provisions ensure signatures remain auditable, secure, and accountable.
• Controls and Safeguards: Under §11.300(a–e), organizations must ensure identification codes and passwords remain unique, require periodic checks and updates, deactivate compromised credentials, and apply transaction safeguards to prevent and detect unauthorized use. Additionally, initial and periodic testing of devices (e.g., tokens or cards) must confirm they function properly and have not been tampered with.

What Are 21 CFR Part 11 Requirements for Passwords and Identification Codes?

The 21 CFR Part 11 requirements for passwords and identification are listed below.

• Implement Unique User Identification (Section 11.300(a)): Each authorized user must have a unique identification code and password combination. Shared credentials are prohibited, as they eliminate individual accountability. Systems should enforce password complexity rules (length, symbols, numbers, mixed case) and use secure methods to store passwords, such as hashing or encryption.
• Prevent Unauthorized Password Use Through Periodic Review (Section 11.300(b)): Passwords and identification codes must be periodically checked, recalled, or revised to prevent compromise. Organizations typically require scheduled password expiration (e.g., 90-day interval), immediate account deactivation when employees leave, and password resets in the event of suspected compromise.
• Establish Loss Management Procedures (Section 11.300(c)): Any device or token storing password data must be deauthorized if lost or stolen. Loss management procedures should include secure identity verification before issuing replacement credentials, documentation of reported losses, and periodic review of loss management effectiveness.
• Avoid Unauthorized Use of Passwords (Section 11.300(d)): Systems must use transaction safeguards to prevent unauthorized use of passwords and identification codes. Safeguards include account lockout after repeated failed login attempts and session timeouts to prevent unauthorized use after inactivity. Other system measures include multi-factor authentication (MFA/2FA) and real-time monitoring for suspicious access attempts.
• Perform Testing of Password/Identification Devices (Section 11.300(e)): Devices that generate or store identification codes or passwords (e.g., smart cards, tokens) must undergo initial and periodic testing. This device testing ensures proper functionality, detects alterations, and confirms device integrity.

What Is a 21 CFR Part 11 Compliant Document Management System?

A 21 CFR Part 11 compliant document management system (DMS) is a validated software application that manages the creation, update, approval, and archival of electronic documents in compliance with FDA requirements for electronic records and electronic signatures. The system must implement comprehensive controls, including user authentication and access controls, time-stamped audit trails, version control, and legally binding electronic signatures, ensuring records are trustworthy, reliable, secure, and compliant with FDA regulations.

In addition, when a DMS is used as a Part 11 system, it must implement revision and change control procedures for user manuals, configuration specifications, and maintenance records, with an audit trail that documents the chronological development and modification of system documentation, as required by 21 CFR 11.10(k).

How Can You Identify if a System Is 21 CFR Part 11 Compliant?

To determine whether a system is 21 CFR Part 11 compliant, the organization must conduct a comprehensive assessment and audit, focusing on various aspects required by the 21 CFR Part 11 regulation. The vendor should provide evidence demonstrating that the system meets key Part 11 requirements, including validation documentation, access and security controls, audit trails, record retention, electronic signature controls, user training provisions, and authority checks. The assessment should include a thorough review of the vendor’s documentation, system capabilities, and built-in controls.

The regulated manufacturer retains ultimate responsibility for ensuring proper system configuration, establishing procedural controls, providing adequate user training, and maintaining ongoing oversight of the system to ensure continued compliance with 21 CFR Part 11.

What Should Be Included in a 21 CFR Part 11 Compliance Checklist?

A 21 CFR Part 11 compliance checklist should include the following.

• Validation (21 CFR 11.10(a)): The system must be validated through documented CSV protocols to prove it consistently maintains accurate, reliable, and secure electronic records.
• Audit Trails (21 CFR 11.10(e), 11.10(k)(2)): A compliant system must automatically generate secure, time-stamped, and immutable audit trails that capture user entries and actions that create, modify, or delete electronic records.
• System Controls (21 CFR 11.10, 11.30): The system must enforce role-based access controls, user authentication, and operational checks, along with additional security measures such as encryption and digital signatures for open systems to protect data integrity.
• Copies of Records (21 CFR 11.10(b)): The system must be capable of producing accurate and complete copies of electronic records with linked signatures, suitable for FDA inspection.
• Record Retention and Retrieval (21 CFR 11.10(c)): Electronic records and their associated audit trails must be securely retained and retrievable throughout their required retention period.
• Electronic Signatures (21 CFR 11.100, 11.200, 11.70): Each electronic signature must be unique, identity-verified, legally equivalent to a handwritten signature, and permanently linked to its corresponding electronic record.
• Access Security (21 CFR 11.300): Systems must enforce unique user IDs and secure authentication mechanisms such as password complexity, expiration, and lockout controls, and procedures must be in place to securely manage lost or compromised credentials.

What Is the Difference Between 21 CFR Part 11 and EU Annex 11?

The main difference between 21 CFR Part 11 and EU Annex 11 is that 21 CFR Part 11 is a U.S. FDA regulation governing electronic records and electronic signatures, while EU Annex 11 is a European Union GMP guideline for computerized systems.

21 CFR Part 11 applies to all FDA-regulated industries in the United States, including pharmaceuticals, biotechnology, and medical devices, and compliance is legally required. EU Annex 11 applies to organizations involved in the manufacture of medicinal products that are subject to EU GMP requirements, focusing on system validation, risk management, personnel roles, supplier oversight, and IT controls throughout the system lifecycle. Unlike 21 CFR Part 11, Annex 11 is a GMP guideline rather than a binding regulation. However, compliance with Annex 11 is enforced through EU GMP regulations and inspections.

How Is 21 CFR Part 11 Related to GAMP 5?

21 CFR Part 11 is related to GAMP 5 because both address the compliance of computerized systems in regulated environments. 21 CFR Part 11 establishes the legal requirements in the United States for electronic records and electronic signatures. GAMP 5 provides international guidance with a risk-based framework and best practices for validating those systems. Applying GAMP 5 supports organizations to maintain compliance with 21 CFR Part 11.

How Does 21 CFR Part 11 Relate to GxP Guidelines?

21 CFR Part 11 relates to GxP guidelines by defining how electronic records and electronic signatures must be managed within GxP-regulated activities. GxP guidelines establish requirements for good practices in manufacturing, laboratory, and clinical processes. In contrast, 21 CFR Part 11 ensures electronic systems supporting these areas maintain data integrity, authenticity, and reliability.

How Does 21 CFR Part 11 Relate to HIPAA?

21 CFR Part 11 relates to the Health Insurance Portability and Accountability Act (HIPAA) because both regulate electronic records, but in different contexts.

21 CFR Part 11 governs the integrity, authenticity, and reliability of electronic records and signatures in FDA-regulated industries. HIPAA ensures the privacy and security of electronic health information. Organizations managing both product data and patient health data must comply with both regulations.

How Does SimplerQMS Ensure Compliance With 21 CFR Part 11?

SimplerQMS ensures compliance with 21 CFR Part 11 by providing a validated electronic quality management system (eQMS) with built-in technical and procedural controls.

SimplerQMS includes the following functionalities expected from 21 CFR Part 11 compliant software.

• System Validation: System validation is delivered as a fully validated system aligned with ISPE GAMP5 principles. SimplerQMS undergoes continuous re-validation for upgrades and patches, with validation protocols, reports, and traceability matrices (RTM) available for FDA inspection.
• Secure Access Control: Secure access control enforces unique user IDs, role-based permissions, and multi-factor authentication, supported by password expiration and lockout policies to prevent unauthorized access.
• Audit Trails: Audit trails generate immutable, computer-generated, time-stamped audit trails that log all record events, including creation, modifications, approvals, and retirements, with user identity, date/time, and reason codes for full traceability.
• Electronic Signatures: Electronic signatures support unique, verifiable e-signatures that meet 21 CFR Part 11 Subpart C requirements, including signature manifestation (name, date, time, purpose) and permanent linkage to records for non-repudiation.
• Data Integrity: Data integrity is ensured through encryption protocols, redundant cloud backups, and disaster recovery testing, protecting electronic records’ authenticity, availability, and resistance to tampering.
• Record Retention: Record retention securely stores records for their entire retention period, with searchable metadata, and ensures they are readily retrievable for FDA inspection and audits.
• Procedural Support: Procedural support provides pre-configured workflows, SOP alignment, training records, and policy templates that help companies meet compliance obligations and demonstrate integration with their QMS.

These capabilities make SimplerQMS a ready-to-use solution for life science organizations seeking full 21 CFR Part 11 compliance.